| abstract |
A modified factor VIII CDNA is disclosed, wherein one or more spliceable nucleotide sequences have been inserted into introns 1 and/or 13 of the wild-type factor VIII cDNA. Further, a process for the production of a biologically active recombinant human factor VIII or its derivative is disclosed, which is performed by cultivating an animal cell line comprising a recombinant expression vector containing said modified factor VIII cDNA. Moreover, a transfer vector for use in the human gene therapy is described which comprises said modified factor VIII cDNA. Finally, the use of recombinant human factor VII and its derivatives for the treatment of hemophilia is disclosed. |